121 related articles for article (PubMed ID: 11856596)
1. Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinoma.
Saad ED; Abbruzzese JL
Crit Rev Oncol Hematol; 2002 Feb; 41(2):205-11. PubMed ID: 11856596
[TBL] [Abstract][Full Text] [Related]
2. Unknown primary carcinoma: randomised studies are needed to identify optimal treatments and their benefits.
Farrugia DC; Norman AR; Nicolson MC; Gore M; Bolodeoku EO; Webb A; Cunningham D
Eur J Cancer; 1996 Dec; 32A(13):2256-61. PubMed ID: 9038607
[TBL] [Abstract][Full Text] [Related]
3. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
Lenzi R; Hess KR; Abbruzzese MC; Raber MN; Ordoñez NG; Abbruzzese JL
J Clin Oncol; 1997 May; 15(5):2056-66. PubMed ID: 9164218
[TBL] [Abstract][Full Text] [Related]
4. [Metastatic carcinoma of unknown origin].
Fizazi K; Culine S
Bull Cancer; 1998 Jul; 85(7):609-17. PubMed ID: 9752267
[TBL] [Abstract][Full Text] [Related]
5. Site-specific Chemotherapy Based on Predicted Primary Site by Pathological Profile for Carcinoma of Unknown Primary Site.
Hasegawa H; Ando M; Yatabe Y; Mitani S; Honda K; Masuishi T; Narita Y; Taniguchi H; Kadowaki S; Ura T; Muro K
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):667-673. PubMed ID: 30196846
[TBL] [Abstract][Full Text] [Related]
6. Carcinoma of unknown primary origin: on the cusp of a new era.
Raber MN
Cancer J; 2010; 16(1):66-7. PubMed ID: 20164693
[No Abstract] [Full Text] [Related]
7. Management of patients with cancer of unknown primary site.
Hainsworth JD; Greco FA
Oncology (Williston Park); 2000 Apr; 14(4):563-74; discussion 574-6, 578-9. PubMed ID: 10826316
[TBL] [Abstract][Full Text] [Related]
8. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients.
Abbruzzese JL; Abbruzzese MC; Hess KR; Raber MN; Lenzi R; Frost P
J Clin Oncol; 1994 Jun; 12(6):1272-80. PubMed ID: 8201389
[TBL] [Abstract][Full Text] [Related]
9. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
Rassy E; Pavlidis N
Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
[TBL] [Abstract][Full Text] [Related]
10. [Carcinoma of unknown primary site. Apropos of 100 patients treated at the Montpellier regional center of cancer prevention].
Culine S; Gazagne L; Ychou M; Romieu G; Fabbro M; Cupissol D; Dubois JB
Rev Med Interne; 1998 Oct; 19(10):713-9. PubMed ID: 9827443
[TBL] [Abstract][Full Text] [Related]
11. Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature.
Amela EY; Lauridant-Philippin G; Cousin S; Ryckewaert T; Adenis A; Penel N
Crit Rev Oncol Hematol; 2012 Nov; 84(2):213-23. PubMed ID: 22503530
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors.
McGuire WP
Curr Probl Cancer; 1998; 22(3):135-77. PubMed ID: 9659570
[TBL] [Abstract][Full Text] [Related]
13. [Carcinoma of unknown primary site (CUP syndrome)].
Sendler A; Strumberg D; Tannapfel A
Chirurg; 2008 Jul; 79(7):689-95; quiz 696. PubMed ID: 18584137
[TBL] [Abstract][Full Text] [Related]
14. Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD
Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
Pentheroudakis G; Briasoulis E; Kalofonos HP; Fountzilas G; Economopoulos T; Samelis G; Koutras A; Karina M; Xiros N; Samantas E; Bamias A; Pavlidis N;
Acta Oncol; 2008; 47(6):1148-55. PubMed ID: 18607872
[TBL] [Abstract][Full Text] [Related]
16. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature.
Lazaridis G; Pentheroudakis G; Fountzilas G; Pavlidis N
Cancer Treat Rev; 2008 Dec; 34(8):693-700. PubMed ID: 18584969
[TBL] [Abstract][Full Text] [Related]
17. Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site.
Culine S; Fabbro M; Ychou M; Romieu G; Cupissol D; Pinguet F
Cancer; 2002 Feb; 94(3):840-6. PubMed ID: 11857320
[TBL] [Abstract][Full Text] [Related]
18. Management of cancer from an unknown primary.
Armstrong AC; Blackhall FH
Expert Opin Pharmacother; 2007 Mar; 8(4):445-55. PubMed ID: 17309339
[TBL] [Abstract][Full Text] [Related]
19. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
[TBL] [Abstract][Full Text] [Related]
20. Unknown primary tumors metastatic to liver.
Ayoub JP; Hess KR; Abbruzzese MC; Lenzi R; Raber MN; Abbruzzese JL
J Clin Oncol; 1998 Jun; 16(6):2105-12. PubMed ID: 9626210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
